Tetralogy of Fallot (TOF) — #1 The Classic Quartet

Tetralogy of Fallot (TOF) — “The Classic Quartet,” explained by one anatomic driver

Tetralogy of Fallot is best understood as a single conotruncal malalignment lesion that produces four predictable downstream findings. In the classic phenotype, anterior and cephalad deviation of the infundibular (outlet) septum re-shapes the outflow geometry: the RV outflow becomes crowded and narrowed, the ventricular septum is left with an outlet VSD, and the aortic root is positioned to receive flow from both ventricles—so the “quartet” is not four separate diseases, but four expressions of one spatial problem. [1–3] (PubMed)

1) The Classic Quartet (what it is—and what it means)

(1) Anterior malalignment (outlet) VSD

• Anatomy: A typically large, nonrestrictive outlet VSD, aligned with the LV outflow because the outlet septum is displaced.
• Clinical meaning: The VSD is rarely the limiting lesion; physiology is governed by RVOT resistance vs SVR (and preload). [1,3] (PubMed)

(2) Overriding aorta

• Anatomy: The aortic root “straddles” the crest of the septum, receiving inflow from both ventricles.
• Practical distinction: In classic TOF, override is often <50%, which is a helpful separator from many DORV phenotypes (where override is typically greater and LV–aortic alignment differs). [1,3] (PubMed)

(3) RV outflow tract obstruction (RVOTO) — the “physiology dial”

• Anatomy (usually multilevel):
1. Infundibular narrowing (fixed + dynamic) driven by outlet septal deviation and RVOT muscular geometry
2. Pulmonary valve stenosis (often small annulus)
3. ± Main/branch PA hypoplasia or stenosis
4. ± Coronary anomalies that constrain RVOT strategies (e.g., coronary crossing the RVOT)
• Clinical meaning: As RVOTO worsens (or SVR falls), R→L shunt increases across the VSD → pulmonary blood flow drops → cyanosis deepens. [1–3] (PubMed)

(4) RV hypertrophy

• Anatomy: Expected pressure-load response to chronic RVOTO.
• Clinical meaning: Matters most for the long-term story—RV remodeling, RV function, and arrhythmia substrate after repair. [2,9,10] (PubMed)

2) “One-figure” spatial rules (high-yield relationships that map to operative thinking)

Your schematic captures several classic, management-shaping relationships:

1. Anterior/cephalad outlet septal deviation → subpulmonary crowding → RVOTO.
2. Posterior/rightward aortic position → aortic override and LVOT alignment via the outlet VSD.
3. Aorto–mitral continuity is usually preserved in classic TOF (contrast: many DORV variants show aortic–mitral discontinuity).
4. The RVOT lesion is typically front-loaded (infundibulum/valve/PA), so repair strategy is fundamentally an RVOT strategy. [1,3] (PubMed)

3) Hemodynamics: why cyanosis happens—and why “tet spells” happen

Baseline physiology (large VSD physiology)

With a large outlet VSD, shunt direction is determined mainly by RVOT resistance vs systemic resistance (SVR) (plus preload):

• ↑ RVOTO and/or ↓ SVR → more R→L streaming → ↓ pulmonary blood flow → ↓ saturation. [1] (PubMed)

Hypercyanotic (“tet”) spells: the vicious cycle

A spell is typically driven by a combination of:

• Dynamic infundibular spasm (catecholamine-sensitive)
• Drop in SVR (crying, fever, vasodilation)
• Reduced preload (dehydration)

→ abrupt fall in pulmonary blood flow and sudden hypoxemia. [1] (PubMed)

4) TOF is a spectrum (name the variants early)

A “textbook” explanation becomes stronger when it states explicitly that TOF is not one anatomy:

• TOF with mild–moderate PS (often fully saturating at rest)
• TOF with severe PS / hypoplastic PAs
• TOF with pulmonary atresia (often MAPCAs)
• Absent pulmonary valve syndrome
• TOF with associated complex anatomy (e.g., AVSD), management-changing subsets [1,3] (PubMed)

5) Contemporary repair philosophy: the RVOT tradeoff (PR vs gradient)

Modern repair aims to balance two truths:

1. Relieve RVOTO sufficiently to ensure durable pulmonary blood flow.
2. Preserve pulmonary valve function when feasible to reduce lifelong pulmonary regurgitation (PR) burden.

Many centers now accept the principle:

• “Valve-sparing when you can; accept a modest gradient when you must.”

This is because TAP can eliminate gradients but often creates chronic PR, which drives late RV dilation, dysfunction, and arrhythmias—key reasons repaired TOF requires lifelong surveillance and frequent adult reintervention. [1–4] (PubMed)

6) The repaired-TOF sequel: RVOT dysfunction is the main long-term storyline

Outcomes are excellent, but the disease evolves into a lifelong RVOT condition.

A. Long-term outcomes (why follow-up must be lifelong)

Across contemporary cohorts, long-term survival is high (e.g., 30-year survival ~68.5–90.5% in a synthesis of studies), but residual RVOT lesions, PR, and arrhythmias are common and often require reinterventions. [3] (PubMed)

B. Pulmonary regurgitation → RV remodeling → timing of PVR

Chronic PR after RVOT reconstruction can be tolerated for years, but evidence supports that RV compensation may eventually fail—and delayed volume unloading may become incompletely reversible in advanced remodeling. This is why contemporary management emphasizes structured timing of pulmonary valve replacement (PVR) rather than “watchful waiting forever.” [4,5,9] (PubMed)

C. Imaging has become decision-critical (CMR-centered)

Cardiac MRI (CMR) is widely treated as the reference standard for repaired TOF because it quantifies:

• RV volumes and function
• PR fraction and RVOT/patch aneurysm geometry
• Additional lesions (TR, residual RVOTO, branch PA stenosis)

…and integrates these into PVR decision-making. [5,9] (PubMed)

D. Surgical vs transcatheter PVR (patient selection is anatomy + physiology)

Transcatheter PVR indications continue to be refined using anatomic and functional imaging (RVOT landing zone, conduit/bioprosthesis suitability, branch PA issues, and hemodynamic goals). [7,9] (PubMed)

E. “Are we chasing the right target?”

Even when RV size improves after PVR, the relationship between RV volumes, symptoms, exercise capacity, and arrhythmia risk is nuanced—supporting a modern approach that considers more than one metric (CMR + symptoms + ECG/arrhythmia profile + RV function + concomitant lesions). [6,8,9] (PubMed)

F. Current “latest thinking” (2024–2025 synthesis)

Recent work emphasizes that late morbidity is often multifactorial—a combined effect of PR, residual RVOTO, coronary constraints, scar substrate, TR, and ventricular interaction—so management increasingly uses integrated, multidisciplinary algorithms (hemodynamics + imaging + electrophysiology). [9,10] (PubMed)

7) Teaching close (high-yield takeaways)

• TOF = one geometry → four findings: anterior/cephalad outlet septal deviation yields outlet VSD + override + RVOTO + RVH. [1–3]
• RVOTO sets the physiology: cyanosis and spells reflect the balance of RVOT resistance vs SVR/preload. [1]
• Repair is a lifetime plan: long-term outcomes hinge on the RVOT strategy and timely management of RVOT dysfunction (PR/stenosis), guided increasingly by CMR and contemporary consensus frameworks. [5,9]

References

[1] Downing TE, Kim YY. Tetralogy of Fallot: General Principles of Management. Cardiol Clin. 2015;33(4):531-41, vii-viii.

[2] Huehnergarth KV, Gurvitz M, Stout KK, Otto CM. Repaired tetralogy of Fallot in the adult: monitoring and management. Heart. 2008;94(12):1663-1669.

[3] van der Ven JPG, van den Bosch E, Bogers AJC, Helbing WA. Current outcomes and treatment of tetralogy of Fallot. F1000Res. 2019;8:F1000 Faculty Rev-1530.

[4] Hauser M, Eicken A, Kuehn A, Hess J, Fratz S, Ewert P, Kaemmerer H. Managing the right ventricular outflow tract for pulmonary regurgitation after tetralogy of Fallot repair. Heart Asia. 2013;5(1):106-111.

[5] Geva T. Repaired tetralogy of Fallot: the roles of cardiovascular magnetic resonance in evaluating pathophysiology and for pulmonary valve replacement decision support. J Cardiovasc Magn Reson. 2011;13(1):9.

[6] Greutmann M. Tetralogy of Fallot, pulmonary valve replacement, and right ventricular volumes: are we chasing the right target? Eur Heart J. 2016;37(10):836-839.

[7] Tretter JT, Friedberg MK, Wald RM, McElhinney DB. Defining and refining indications for transcatheter pulmonary valve replacement in patients with repaired tetralogy of Fallot: Contributions from anatomical and functional imaging. Int J Cardiol. 2016;221:916-925.

[8] Latus H, Tutarel O. Outcomes after pulmonary valve replacement in patients with repaired tetralogy of Fallot: end of a success story? Heart. 2018;104(9):717-718.

[9] Geva T, Wald RM, Bucholz E, Cnota JF, McElhinney DB, Mercer-Rosa LM, Mery CM, Miles AL, Moore J; American Heart Association Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular Surgery and Anesthesia; Council on Clinical Cardiology; and Council on Cardiovascular and Stroke Nursing. Long-Term Management of Right Ventricular Outflow Tract Dysfunction in Repaired Tetralogy of Fallot: A Scientific Statement From the American Heart Association. Circulation. 2024;150(25):e689-e707.

[10] Fan Q, Wang Y, An Q, Ling Y. Right ventricular dysfunction following tetralogy of Fallot correction: anatomical determinants and therapeutic strategies. Int J Surg. 2025;111(6):3979-3988.